Aventis Submits Taxotere sNDA In Early-Stage Breast Cancer; Two More Planned By Early 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
The filing is the second of four supplements planned for the oncologic over the next year. A prostate cancer sNDA was submitted earlier in the year; filings for gastric cancer and head and neck cancer are expected.
You may also be interested in...
Aventis Taxotere For Prostate Cancer Clears FDA With 2.5 Month Survival Benefit
Taxotere is the first drug to demonstrate a survival benefit in hormone refractory patients, FDA said. Aventis is investigating docetaxel as first-line therapy.
Aventis Taxotere For Prostate Cancer Clears FDA With 2.5 Month Survival Benefit
Taxotere is the first drug to demonstrate a survival benefit in hormone refractory patients, FDA said. Aventis is investigating docetaxel as first-line therapy.
Aventis Defense Against Sanofi Begins With Genasense; Ketek, Exubera Also Overlooked, Firm Says
All three brands have blockbuster potential, Aventis says. The company predicts growth of 7%-8% in 2004 revenues, but says divestments of older brands may help enhance margins.